Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge.

Kask AS, Chen X, Marshak JO, Dong L, Saracino M, Chen D, Jarrahian C, Kendall MA, Koelle DM.

Vaccine. 2010 Nov 3;28(47):7483-91. doi: 10.1016/j.vaccine.2010.09.014. Epub 2010 Sep 17.

PMID:
20851091
2.

Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.

Jazayeri M, Soleimanjahi H, Fotouhi F, Pakravan N.

Comp Immunol Microbiol Infect Dis. 2009 Sep;32(5):453-61. doi: 10.1016/j.cimid.2008.05.002. Epub 2008 Jun 20.

PMID:
18571235
3.

Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.

Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, Baloglu S, Anderson SF, DiNapoli JM, Londoño-Hayes P, Parrington M, Almond J, Kleanthous H.

PLoS One. 2012;7(10):e46714. doi: 10.1371/journal.pone.0046714. Epub 2012 Oct 11.

4.

Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays.

Chen X, Kask AS, Crichton ML, McNeilly C, Yukiko S, Dong L, Marshak JO, Jarrahian C, Fernando GJ, Chen D, Koelle DM, Kendall MA.

J Control Release. 2010 Dec 20;148(3):327-33. doi: 10.1016/j.jconrel.2010.09.001. Epub 2010 Sep 17.

PMID:
20850487
5.

A mucosal vaccination approach for herpes simplex virus type 2.

Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, Nie S, Guberski DL, Yang K.

Vaccine. 2011 Jan 29;29(5):1090-8. doi: 10.1016/j.vaccine.2010.11.076. Epub 2010 Dec 4.

6.

Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.

Wizel B, Persson J, Thörn K, Nagy E, Harandi AM.

Vaccine. 2012 Jun 19;30(29):4361-8. doi: 10.1016/j.vaccine.2012.02.019.

PMID:
22682292
7.

Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE.

J Virol. 2005 Jan;79(1):410-8. Erratum in: J Virol. 2005 Apr;79(7):4554.

10.

Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI.

Vaccine. 2008 Jul 29;26(32):4034-40. doi: 10.1016/j.vaccine.2008.05.022. Epub 2008 Jun 2.

11.

Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D.

Domingo C, Gadea I, Pardeiro M, Castilla C, Fernández S, Fernández-Clua MA, De la Cruz Troca JJ, Punzón C, Soriano F, Fresno M, Tabarés E.

Vaccine. 2003 Sep 8;21(25-26):3565-74.

PMID:
12922084
13.

Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.

El-Ghorr AA, Williams RM, Heap C, Norval M.

FEMS Immunol Med Microbiol. 2000 Dec;29(4):255-61.

14.

Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, Ginsberg R, Ciccarelli R, Corey L, Koelle DM.

Clin Vaccine Immunol. 2008 Nov;15(11):1638-43. doi: 10.1128/CVI.00167-08. Epub 2008 Sep 10.

15.

DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR.

Vaccine. 1996 Sep;14(13):1230-4.

PMID:
8961510
17.

Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.

Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F.

FEMS Immunol Med Microbiol. 2008 Oct;54(1):18-26. doi: 10.1111/j.1574-695X.2008.00438.x. Epub 2008 Jul 21.

18.

Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Görander S, Harandi AM, Lindqvist M, Bergström T, Liljeqvist JÅ.

J Virol. 2012 Jul;86(14):7544-53. doi: 10.1128/JVI.00186-12. Epub 2012 May 2.

19.

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.

Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL.

J Immunol. 2001 Mar 1;166(5):3451-7.

20.

An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.

Dutton JL, Woo WP, Chandra J, Xu Y, Li B, Finlayson N, Griffin P, Frazer IH.

Hum Vaccin Immunother. 2016 Dec;12(12):3079-3088. doi: 10.1080/21645515.2016.1221872.

Supplemental Content

Support Center